Clinical Drug Experience Knowledgebase

cyclophosphamide (cytoxan) (2 trials)

dexamethasone (2 trials)

docetaxel (taxotere) (2 trials)

doxorubicin (Doxil) (2 trials)

epirubicin (ellence) (1 trial)

ibrutinib (imbruvica) (1 trial)

prednisone (meticorten) (2 trials)

rituximab (rituxan) (2 trials)

thymalfasin (zadaxin) (1 trial)

carboplatin (paraplatin) (1 trial)

lenalidomide (revlimid) (1 trial)

paclitaxel (taxol) (1 trial)

tirofiban (aggrastat) (1 trial)

vincristine (oncovin) (1 trial)

zanubrutinib (Brukinsa) (1 trial)

anlotinib (1 trial)

azacitidine (vidaza) (2 trials)

bortezomib (velcade) (1 trial)

chidamide (1 trial)

febuxostat (uloric) (1 trial)

furmonertinib (Ives) (1 trial)

imatinib (gleevec) (1 trial)

mitoxantrone (novantrone) (1 trial)

pomalidomide (pomalyst) (1 trial)

ruxolitinib (jakafi) (1 trial)

tgrx-326 (1 trial)

venetoclax (venclexta) (1 trial)

CD19-7×19 CAR-T cells (1 trial)

tislelizumab (1 trial)

mannitol (Osmitrol) (1 trial)

midodrine (proamatine) (1 trial)

polyethylene glycol (4 trials)

salvianolate (1 trial)

sodium chloride (1 trial)